Christian J. Leumann

TL;DR: The formula I in the form of the racemates or enantiomers thereof, in which R 1 and R 2 independently of one another are hydrogen or a protective group, and B is a purine or pyrimidine radical or an analogue thereof, can be used as antiviral active ingredients or for the preparation of biologically active oligonucleotides as mentioned in this paper.

TL;DR: This review focuses on recent advances in the de novo design of nucleoside analogues with improved binding properties and tries to summarize scope and limitations of this design principle.

TL;DR: Although current naked AONs do not enter the heart or cross the blood-brain barrier to any substantial extent, it is shown that systemic delivery of tcDNA-AONs promotes a high degree of rescue of dystrophin expression in skeletal muscles, the heart and, to a lesser extent, the brain.

TL;DR: CD spectroscopic structural investigations indicated that tricyclo-DNA containing duplexes preferrably exist in an A-conformation, a fact which is in agreement with results from molecular modeling.

TL;DR: New bases that specifically recognize pyrimidine-purine inversion sites as well as sugar modifications, for example, the 2'-aminoethoxy-oligon nucleotides or oligonucleotides based on the locked nucleic acid sugar unit, which greatly enhance triplex stability and alleviate in part the sequence restriction constraints.